Pricing Log in Create free account
Saturday 17 October 2026 Export IRWD’s income statement to Excel — free account

Ironwood Pharmaceuticals, Inc.

IRWD Healthcare Drug Manufacturers Specialty & Generic

Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.6%, EPS grew 106.7%, free cash flow grew 486.7% and total debt was flat, each against the same quarter a year earlier.

3.50 0.27 −7.16%
Market cap
$623.0M
P/E
4.4×
Fwd P/E
2.8×
Dividend yield
—
F-score
5/9
Altman Z
−3.75
Beneish M
−4.20
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 22.62
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — 1 6 1 — — 1 1 — — —
Insider Ownership 3.23%

Capital & Financial Ratios $m

Market Cap 622.95
Revenue 389.32
Net Income 129.87
Free Cash Flow 185.56
Net Debt 305.87
Current Ratio 6.06 (at or above 1.5: strong)
Debt/Equity (2.38) (negative: negative equity)
P/E ratio 4.39
Fwd P/E 2.81
P/S ratio 1.48
P/B ratio 0.00
Past 5Y EPS Growth (25.65%) (below 0%: weak)
This Y EPS Growth 715.56% (at or above 15%: strong)
Next Y EPS Growth 7.63%
Next Y revenue growth 59.18% (at or above 10%: strong)
Next 5Y EPS Growth 112.04% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.8×, against a ten-year median of 4.5×; over the ten years it ranged from 1.9× in 2025 to 9.1× in 2017.
P/E against its own 10 years 22.01%
10-year low 10-year high
P/S against its own 10 years 7.67%
10-year low 10-year high
EV/Sales against its own 10 years 7.96%
10-year low 10-year high
EV/FCF against its own 10 years 9.02%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 92 89 215 79
Receivables 129 82 47 113
Inventory — — — —
Other — — — —
233 182 274 199
2023 2024 2025 Q'26
Payables 8 2 3 1
ST’ Debt 200 — 200 —
Other — — — —
276 39 242 33

Compound Annual Growth %

10y 5y 3y
Sales 7.07% (5.33%) (10.32%)
Cash Flow 0.00% (5.53%) (22.58%)
Earnings 0.00% (25.72%) (48.42%)
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 107 113 — — —
’25 41 85 122 48 296
’24 75 94 92 91 351
’23 104 107 114 118 443
’22 98 97 109 107 411
’21 89 104 104 117 414
’20 80 89 103 117 390
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 5 58 — — —
’25 20 (15) 48 75 127
’24 45 33 10 15 104
’23 80 35 32 36 183
’22 64 61 69 79 274
’21 74 49 75 65 262
’20 44 20 54 52 169
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 5 58 — — —
’25 20 (15) 48 75 127
’24 45 33 10 15 103
’23 80 35 32 36 183
’22 64 61 69 79 274
’21 74 49 75 64 262
’20 42 20 54 51 167
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.24 0.31 — — —
’25 (0.23) 0.14 0.23 (0.01) 0.15
’24 (0.03) (0.01) 0.02 0.01 0.01
’23 0.25 (6.84) 0.09 (0.01) (6.45)
’22 0.21 0.21 0.28 0.27 0.96
’21 0.25 2.39 0.34 0.25 3.21
’20 0.02 0.16 0.21 0.27 0.66
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 6.16 11.25 7.60 7.91 7.99 8.78 9.73 8.07 3.06 0.53

Analyst estimates 2026–2028

Powerpack
High 14.15 16.70 17.76 14.10 14.06 14.27 12.95 12.66 15.70 4.78
People
People Employees 674 730 515 317 232 219 219 267 253 100
Revenue/emp, $m 0.41 0.41 0.67 1.35 1.68 1.89 1.87 1.66 1.39 2.96
Income, $m
Income, $m Revenue 274 298 347 428 390 414 411 443 351 296
Gross margin, % 99.32 93.60 90.55 94.43 99.19 100.00 100.00 100.00 100.00 100.00
EBT (82) (55) (194) 59 109 201 252 (948) 65 70
EBT margin, % (29.83) (18.41) (56.01) 13.76 27.95 48.50 61.48 (214.14) 18.55 23.65
Net income (82) (117) (282) 22 106 528 175 (1,032) 1 24
Depreciation 11 13 12 6 4 2 1 2 2 2
Per share, $
Per share, $ Revenue 1.89 2.00 2.27 2.75 2.44 2.55 2.66 2.85 2.21 1.83
Earnings (0.56) (0.78) (1.85) 0.14 0.67 3.26 1.13 (6.45) 0.01 0.15
Cash flow (0.18) (0.68) (0.46) 0.07 1.06 1.61 1.77 1.18 0.65 0.79
Capex (0.72) (0.02) 0.01 (0.04) (0.01) 0.00 0.00 0.00 0.00 0.00
Free cash flow (0.90) (0.69) (0.46) 0.02 1.05 1.61 1.77 1.18 0.65 0.78
Book value 0.46 0.07 (1.29) (0.60) 0.39 3.73 4.23 (2.23) (1.89) (1.62)
Shares, m 145 149 153 156 159 162 154 155 159 162
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 17.00 3.58 10.76 0.00 0.00 21.38
P/S 6.59 6.39 3.82 4.85 4.66 4.57 4.61 4.36 2.01 1.84
P/B 27.05 193.50 0.00 0.00 28.99 3.12 2.90 0.00 0.00 0.00
EV/Sales 6.81 6.97 4.51 5.39 4.84 4.21 3.98 5.73 3.98 3.09
EV/FCF (62.37) (20.11) (22.45) 606.61 11.29 6.66 5.98 13.84 13.54 7.20
Cash, $m
Cash, $m Operating cash flow (26) (101) (71) 11 169 262 274 183 104 127
Capex (104) (3) 1 (7) (2) 0 0 0 0 0
Free cash flow (130) (103) (70) 4 167 262 274 183 103 127
Balance, $m
Balance, $m Working capital 289 246 147 266 464 584 755 (43) 144 32
Total debt 373 400 414 409 433 473 399 698 584 585
Net debt 68 179 239 231 69 (149) (258) 606 495 369
Shareholders’ equity 67 10 (196) (93) 63 606 652 (346) (301) (262)
Returns, %
Returns, % ROA (12.30) (17.78) (60.22) 5.85 22.07 62.68 15.72 (127.54) 0.21 6.42
ROIC (24.14) (5.09) (218.71) 54.61 67.89 31.74 39.69 (227.77) 29.99 57.33
ROE (100.97) (305.46) 302.77 (14.85) (693.71) 158.09 27.83 (654.88) (0.27) (8.53)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Ironwood Pharmaceuticals, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
COLL Collegium Pharmaceutical, Inc. $754.6M 15.2× 12.5× +6.32% (above 0%: growing) n/m −2.14% (below 0%: shrinking) 55.18% 1.85% Compare
IRWD Ironwood Pharmaceuticals, Inc. $623.0M 4.4× 2.8× +32.62% (above 0%: growing) +106.67% (above 0%: growing) +486.70% (above 0%: growing) 100.00% 70.16%
AQST Aquestive Therapeutics, Inc. $509.6M — (loss-making) — (loss-making) +38.15% (above 0%: growing) n/m −20.35% (below 0%: shrinking) 70.93% (59.51%) Compare
EVO Evotec AG $504.4M — (loss-making) — (loss-making) −12.98% (below 0%: shrinking) n/m −9,727.20% (below 0%: shrinking) (1.00%) (77.50%) Compare
EOLS Evolus, Inc. $500.0M — (loss-making) — (loss-making) +21.18% (above 0%: growing) n/m +84.90% (above 0%: growing) 68.00% (5.40%) Compare
TLRY Tilray Brands, Inc. $474.4M — (loss-making) — (loss-making) +22.74% (above 0%: growing) n/m −36.60% (below 0%: shrinking) 30.14% (9.35%) Compare
KMDA Kamada Ltd. $451.7M 20.4× — (loss-making) +22.72% (above 0%: growing) +23.08% (above 0%: growing) +165.71% (above 0%: growing) 40.91% 17.32% Compare
TKNO Alpha Teknova, Inc. $408.0M — (loss-making) — (loss-making) +18.45% (above 0%: growing) n/m +74.18% (above 0%: growing) 40.09% (23.72%) Compare
EBS Emergent Biosolutions Inc. $368.1M — (loss-making) — (loss-making) +66.29% (above 0%: growing) n/m −47.68% (below 0%: shrinking) 58.56% (53.39%) Compare
Median of peers $487.2M — — +21.95% — −11.24% 48.05% (16.53%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Ironwood Pharmaceuticals, Inc. (IRWD) key facts

  • Concern: Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024.
  • Ironwood Pharmaceuticals, Inc. (IRWD) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, IRWD traded at $3.50, a market capitalization of $623.0 million.
  • Return on equity was −8.53% and debt-to-equity -2.38.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −3.75 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Ironwood Pharmaceuticals, Inc. (IRWD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IRWD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com